[1] |
XU Weijia, PENG Qi, HUANG Haiyu, ZHANG Leijiao, XIAO Hua, WU Xue.
285 cases of adverse drug reaction related to new antineoplastic drugs
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 199-203.
|
[2] |
MENG Kangkang, LIU Saiyue.
After-marketing safety of coenzyme Q10 for injection
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 795-798.
|
[3] |
ZHANG Lei, LYU Jian, XIE Yanming.
Efficacy and safety of Houpupaiqi Mixture in the treatment of postoperative lieus: a Meta-analysis
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 799-806.
|
[4] |
QIN Guilan, ZHOU Muzi, JI Zhaoshuai, MAO Qiantai, AI Chao.
One case of acute constipation induced by semaglutide injection
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 833-835.
|
[5] |
CHENG Fengjingming, LYU Jian, XIE Yanming.
Efficacy and safety of compound salvia miltiorrhiza spray/aerosol for angina pectoris due to coronary artery disease: a Meta analysis
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 536-543.
|
[6] |
SU Xinxin, LYU Jian, XIE Yanming.
Efficacy and safety of Toutongning capsules in the treatment of chronic headache: a Meta-analysis
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 433-440.
|
[7] |
QIAN Peipei, CAO Kai, XU Bingxin, YING Yabin, ZHAO Ningke, ZHAO Liang.
Signal detection and analysis of adverse events related to nirmatrelvir/ritonavir based on JADER database
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1154-1158.
|
[8] |
SUN Yixin, LIU Zhike, ZHAN Siyan.
Scoping review of near real-time surveillance of vaccine safety
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 61-67.
|
[9] |
YU Ji, RAN Shuo.
Evaluation of drug use during applications of clinical pathways in patients with STEMI based on DUR and DUE
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(6): 674-679.
|
[10] |
ZHANG Ruili, SU Shuang, JIANG Jiming, ZHANG Jing.
Thirty-six cases of adverse drug reactions/events caused by Xinhuang tablets
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(5): 561-563.
|
[11] |
ZHU Na, KAN Xiaohong, WU Xinli, DING Haihua, XUE Shuya, ZHANG Yunling.
113 reports of adverse drug reactions induced by fluoroquinolones in patients with tuberculosis
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(4): 404-407.
|
[12] |
LI Yu, FAN Huihui, FENG Xiaojun, ZHANG Yonghuang, CHEN Qin, WANG Yunhong, CHEN Chuantao, ZHANG Lei, SHI Tianlu.
Association between ABCB1 C3435T polymorphisms and methotrexate-induced toxicity in childhood acute lymphoblastic leukemia: Meta analysis
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(4): 421-425.
|
[13] |
HUANG Li, WEI Long, LI Hemei, YI Dan.
Literature review of 58 cases of adverse drug reactions induced by flurbiprofen
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(4): 436-440.
|
[14] |
HUANG Can, QI Lamei, LI Duohui, CHEN Zhaolin, JU Jing.
A analysis of safety of 73 users of carrelizumab
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(3): 292-295.
|
[15] |
CHEN Congcong, TAN Ruijuan, WANG Lidan, ZHANG Yuanyuan, HU Xiaoyan, CHEN Yuanyuan.
Clinical characteristics and risk factors of thrombocytopenia induced by fluoroquinolones
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(3): 306-309.
|